A recent study led by scientists at Dana-Farber Cancer Institute found an slightly increased risk of fatal side effects in certain patients treated with VEGF-tyrosine kinase inhibitors. Dr. Toni Choueiri, who led the study, explains what physicians need to know about their patients' medical histories, and how they can help educate patients about the benefits and potential risks of these therapies.
Palliative care is given in a doctors office, hospital, cancer center, long-term care facility, or your home. Your doctor or a hospital social worker will help you find palliative care.
"We observed encouraging clinical and immunologic responses which correlated with prolonged survival," said Robert Figlin M.D., director of the Division of Hematology/Oncology at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute and presenter of the new findings.
Help researchers and meet others who are dealing with renal cancers in a multimedia, feature-rich, environment. Login with Facebook or your email and meet survivors and their families. Better than Facebook, because your participation will help those who want to cure kidney cancer.
Join us for a live Facebook chat every Tuesday at 8 a.m. and 8 p.m. Central. The Kidney Cancer Association has more than 45,000 friends on Facebook and anyone interested in the eradication of death and suffering from this disease is welcome to join.
14.7 months median progression free survival; 28% confirmed partial response rate & 72% disease control rate at week 16.
Navigating Treatment Decisions for Your Metastatic Renal Cell Carcinoma, by David Quinn, PhD, MBBS, FRACP
Searchable list of abstracts submitted for the 2012 ASCO Genitourinary Cancers Symposium, held this week in San Francisco.
Ulka Vaishampayan, MD writes: Biomarkers represent the future of renal cancer therapeutics. With six new targeted-therapy agents receiving U.S. Food and Drug Administration approvals, and many more maturing toward becoming established therapies, optimization of these treatments has become a dire need of the moment. Current prognostic information is predominantly reliant on patient and tumor characteristics and is derived from basic clinical history, physical examination, and laboratory tests.
The well-informed kidney cancer patient is the empowered patient, but is it wise to rely on the interpretation of medical information by other lay people? Perhaps not. In this podcast we discuss the importance of doing your own fact-finding.